Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Recurrence 1Hereditary Sensory and Autonomic Neuropathies 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 54Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × PX-866 × Gastrointestinal × Clear all
NCT01252628 2018-05-16

Phase 1 and 2 Study of PX-866 and Cetuximab

Seagen Inc.

Phase 1/2 Completed
178 enrolled
Gastrointestinal

Carcinoma, Squamous Cell, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡